Leukocyte-derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis

Batycka-Baran, Aleksandra; Hattinger, E.; Zwicker, Stephanie; Summer, Burkhard; Howard, O. M. Zack; Thomas, Peter A.; Szepietowski, Jacek C.; Ruzicka, Thomas; Prinz, Jörg C.; Wolf, Ronald

doi:10.1016/j.jdermsci.2015.05.007

Cited by 52 publications

(65 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is enrolled in the inflammatory process, especially in the epidermis where its level is increased and amplified acting as chemoattractants for the immune cells (Xia, Braunstein, Toomey, Zhong, & Rao, ). The current study showed a high level of this protein among patients with acne vulgaris in both groups before therapeutic trial, which coinsides with the results of Borovaya et al () and Batycka‐Baran et al (), Batycka‐Baran et al () who also found a significant increase of this antimicrobial peptide in chronic inflammatory skin lesions of different dermatoses, which was caused by epidermal keratinocytes overproduction. Nevertheless, although the upregulation of S100a7a peptide has been documented in acne vulgaris condition, keratinocytes overproduction in acne vulgaris was not determined (Borovaya et al, ).…”

Section: Discussionsupporting

confidence: 91%

Downregulation of S100a7a antimicrobial peptide in acne vulgaris patients after isotretinoin therapy

Al‐Sudany¹,

Mohammed

Alrifai³

2019

Dermatologic Therapy

View full text Add to dashboard Cite

The S100a7a protein is expressed in keratinocytes, its level is increased in acne condition. As isotretinoin therapy is known to alter some of S100 peptides, these could be important specific targets for acne therapy and may have an important role in clinical remission. A randomized controlled trial was held in a dermatology clinic in Baghdad, where 30 patients with moderate to severe acne vulgaris condition aged 16–31 years were enrolled. Five milliliters of venous blood samples were taken before and after 6 weeks of isotretinoin therapeutic trial. A placebo‐control group of 26 acne patients was also enrolled. The S100a7a peptide was measured in both groups using the ELISA technique before and after the trial. High levels of serum S100a7a were found in acne patients of both groups before therapeutic trial. Following the trial, a significant statistical difference (p = .0003) was noticed between mean S100a7a protein level of study and control groups. By comparing the mean S100a7a protein level before and after isotretinoin therapy in the study group, a highly significant statistical difference was also found (p = .001). The current study showed a downregulatory effect of isotretinoin therapy on the S100a7a peptide mean level.

show abstract

Section: Discussionsupporting

confidence: 91%

Downregulation of S100a7a antimicrobial peptide in acne vulgaris patients after isotretinoin therapy

Al‐Sudany¹,

Mohammed

Alrifai³

2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Circulating psoriasin and koebnerisin are probably derived from high cutaneous production in involved skin, and may contribute to skin and systemic inflammation in psoriasis, which in turn may favour the development and progression of atherosclerotic processes in psoriasis …”

Section: Discussionmentioning

confidence: 99%

“…Recent research has highlighted the role of koebnerisin and psoriasin as systemic proinflammatory mediators in psoriasis, and suggested that they may contribute to both skin and systemic inflammation. Therefore, they could be potential markers for increased cardiovascular risk and metabolic comorbidities in psoriasis …”

Section: Introductionmentioning

confidence: 99%

Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Increasing evidence suggests that hS100A7 plays critical roles in amplifying the inflammatory process in psoriatic skin, perpetuating the disease phenotype. [42, 43] In human cultured keratinocytes, hS100A7 also induce the expression of several differentiation markers, which are overexpressed in psoriatic skin. [44, 45] In our study, we confirmed that mS100a7a15 was overexpressed in psoriasis model skin.…”

Section: Discussionmentioning

confidence: 99%

“…Delphinidin was found to suppress hS100A7 expression in a 3D psoriatic skin equivalent model, and treatment with narrow-band UVB phototherapy induces a reduced production of hS100A7 in peripheral blood mononuclear cells in psoriatic patients. [43, 46] So, hS100A7 may serve as a potential therapeutic target for psoriasis with relatively few side effects.…”

Section: Discussionmentioning

confidence: 99%

Human S100A7 Induces Mature Interleukin1α Expression by RAGE-p38 MAPK-Calpain1 Pathway in Psoriasis

Jing

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Psoriatic keratinocytes express exaggerated levels of inflammatory cytokines, and show aberrant hyperproliferation and terminal differentiation in the pathogenesis of psoriasis. The antimicrobial protein hS100A7 (psoriasin) has been found highly expressed in psoriatic skin, but the mechanism and physiological function remain largely unknown. We observed that hS100A7 induces mature interleukin 1α (17kDa) expression in normal human epidermal keratinocytes, which is dependent on RAGE-p38 MAPK and calpain-1 as the inhibitors or knockdown of them completely decreased the expression of mature interleukin1α. Then, we proved mS100a7a15, mature IL-1α and calpain-1 were highly expressed in imquimod-induced psoriasis model and mouse IL-17a-neutralizing antibody treatment attenuated mS100a7a15 expression. At last, PD 151746 (calpain-1 inhibitor) treatment decreased epidermal thickness in imquimod-induced psoriasis model. Taken together, our results suggest that mature IL-1α induced by hS100A7 is via RAGE-p38 MAPK and calpain-1 pathway in keratinocyte and this mechanism may play an important role during psoriasis.

show abstract

Leukocyte-derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis

Cited by 52 publications

References 32 publications

Downregulation of S100a7a antimicrobial peptide in acne vulgaris patients after isotretinoin therapy

Downregulation of S100a7a antimicrobial peptide in acne vulgaris patients after isotretinoin therapy

Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis

Human S100A7 Induces Mature Interleukin1α Expression by RAGE-p38 MAPK-Calpain1 Pathway in Psoriasis

Contact Info

Product

Resources

About